Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ChromaDex Corporation
< Previous
1
2
3
Next >
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
June 24, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
June 13, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
June 07, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
June 04, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
May 23, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
May 22, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Corporation Reports First Quarter 2024 Financial Results
May 08, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
April 25, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
April 30, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
April 24, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
April 23, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
March 26, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
March 06, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
February 21, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
February 05, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
January 26, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
December 20, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
November 30, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
November 15, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
November 09, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
November 08, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
November 01, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
October 31, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
October 26, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
August 24, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
October 02, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
August 09, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness
August 08, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series
August 07, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
August 02, 2023
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.